Cargando…

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC. PATIENTS AND METHODS: This o...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Bi, Feng, Gu, Shanzhi, Bai, Yuxian, Chen, Zhendong, Wang, Zishu, Ying, Jieer, Lu, Yinying, Meng, Zhiqiang, Pan, Hongming, Yang, Ping, Zhang, Helong, Chen, Xi, Xu, Aibing, Cui, Chengxu, Zhu, Bo, Wu, Jian, Xin, Xiaoli, Wang, Jufeng, Shan, Jinlu, Chen, Junhui, Zheng, Zhendong, Xu, Li, Wen, Xiaoyu, You, Zhenyu, Ren, Zhenggang, Liu, Xiufeng, Qiu, Meng, Wu, Liqing, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445562/
https://www.ncbi.nlm.nih.gov/pubmed/34185551
http://dx.doi.org/10.1200/JCO.21.00163